Results 231 to 240 of about 6,427,330 (272)
Some of the next articles are maybe not open access.

Bortezomib In Mantle Cell Lymphoma

Future Oncology, 2008
Mantle cell lymphoma (MCL) represents 6% of non-Hodgkin lymphomas, but is one of the most active fields of clinical investigation. Unfortunately, there is still no standard or curative therapy in MCL. Front-line therapy appears to benefit from intensification either through high-dose therapy with stem cell transplant consolidation or dose-intense ...
K Stephen, Suh, Andre, Goy
openaire   +2 more sources

Mantle-Cell Lymphomas of the Skin

Dermatologic Clinics, 1994
The skin lesions of two elderly women lead us to the diagnosis of small cleaved lymphocytic B-cell non-Hodgkin's lymphoma, TNM stage IVb after clinical staging examinations. Relapses occurred within less than 1 year. Morphology, enzymhistochemistry (alkaline phosphatase in the first case), and immunohistochemistry (CD 5 positivity in the second case ...
M L, Geerts, A M, Busschots
openaire   +2 more sources

Indolent mantle cell lymphoma

Leukemia & Lymphoma, 2013
Over the past decade, it has become increasingly clear that mantle cell lymphoma (MCL) is a more heterogeneous disease than originally recognized. Several groups have reported on a subgroup of patients with a less aggressive course than expected resulting in the term "indolent MCL".
Eric D, Hsi, Peter, Martin
openaire   +2 more sources

Blastoid Mantle Cell Lymphoma

Hematology/Oncology Clinics of North America, 2020
Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due to their rarity.
Preetesh, Jain, Michael, Wang
openaire   +2 more sources

Ibrutinib for Mantle Cell Lymphoma

Future Oncology, 2016
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma. Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor. Early clinical trials have demonstrated excellent tolerability and a modest side-effect profile in relapsed/refractory MCL.
David L, Tucker, Simon A, Rule
openaire   +2 more sources

Lenalidomide for mantle cell lymphoma

Expert Review of Hematology, 2015
Mantle cell lymphoma accounts for 6% of all non-Hodgkin lymphomas. It is a biologically and clinically heterogeneous disease and treatment may be difficult, since most patients present at an older age, being unable to undergo intensive chemotherapy. Lenalidomide is an approved medication for relapsed mantle cell lymphoma in patients who received at ...
Alan P, Skarbnik, Andre H, Goy
openaire   +2 more sources

Mantle-Cell Lymphoma

New England Journal of Medicine, 2022
James O, Armitage, Dan L, Longo
openaire   +4 more sources

Histopathology of Mantle Cell Lymphoma

Seminars in Hematology, 2011
Mantle cell lymphoma (MCL) is a relatively rare lymphoma, accounting for less than 10% only of all lymphomas. Its morphology is quite homogeneous, but it varies strikingly in about 10% of the cases, making the diagnosis of MCL challenging for histopathologists. The definition of the disease was greatly influenced by the discovery of the translocation t(
openaire   +2 more sources

Mantle cell lymphoma diagnosis

Annales de biologie clinique, 2013
Recent classifications of non-Hodgkin's lymphomas based on combination of morphologic, immunophenotypic, and cytogenetic criteria have individualized mantle cell lymphoma (MCL). This clinico-biological entity which accounts for 3 to 10% of all non-Hodgkin's lymphomas, now appears to be a biological and therapeutic model for the understanding and ...
Mohammed, Choukri   +7 more
openaire   +2 more sources

The Epigenetics of Mantle Cell Lymphoma

Current Treatment Options in Oncology, 2007
There is no consensus treatment for newly diagnosed mantle cell lymphoma. The CHOP + rituximab and hyperCVAD + rituximab regimens are most commonly used. The former is limited by relatively lower rates of complete remission (CR) and frequent relapses. The latter is limited by toxicities, especially in older patients, and relapses that occur later than ...
Margaret, Yu, Elliot, Epner
openaire   +2 more sources

Home - About - Disclaimer - Privacy